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Background. Type 1 diabetes mellitus is characterized by an inability to produce insulin endogenously. Based on a series of
histopathology studies of patients with recent onset of the disease, it is commonly stated that the onset of clinical symptoms
corresponds to an 80-95% reduction in beta cell mass. Motivated by the clinical importance of the degree of beta cell
destruction at onset, a meta-analysis was used to determine the validity of this common wisdom. Methods and Findings. The
histopathology results identifying insulin containing islets in patients younger than 20 years of age were extracted from three
different studies. The results for 105 patients were stratified by duration of diabetic symptoms and age at onset. Linear
regression and a non-parametric bootstrap approach were used to determine the dependence of residual beta cell mass to age
at onset. The percentage reduction in beta cell mass was highly correlated (p,0.001) with the age of onset with the greatest
reduction in beta cell mass in the youngest patients. As this trend had not been previously observed, an alternative
physiology-based model is proposed that captures this age-dependence. Conclusions. The severity in beta cell reduction at
onset decreased with age where, on average, a 40% reduction in beta cell mass was sufficient to precipitate clinical symptoms
at 20 years of age. The observed trend was consistent with a physiology-based model where the threshold for onset is based
upon a dynamic balance between insulin-production capacity, which is proportional to beta cell mass, and insulin demand,
which is proportional to body weight.
Citation: Klinke DJ (2008) Extent of Beta Cell Destruction Is Important but Insufficient to Predict the Onset of Type 1 Diabetes Mellitus. PLoS ONE 3(1):
e1374. doi:10.1371/journal.pone.0001374
INTRODUCTION
Type 1 diabetes mellitus is characterized by an impaired ability to
produce insulin due to the progressive and selective destruction of
beta cells in the pancreatic islets of Langerhans [1]. The
destruction of beta cells is attributed to a variety of environmental
and genetic risk factors [2] and results in the inability to maintain
glucose homeostasis. While there are promising therapeutics in the
drug pipeline (e.g. anti-CD3 [3]), there are currently no treatments
available to stop the progressive destruction of insulin-producing
beta cells. The standard of care for many patients with Type 1
diabetes mellitus is currently exogenous insulin or insulin analog
therapy [4]. The requirement for exogenous insulin, associated
with reduced control of glucose homeostasis, results in an
increased incidence of significant long-term side effects [5]. Any
effort to prolong endogenous insulin production may have a
significant impact on the long-term quality of life for patients with
Type 1 diabetes mellitus. Clinical management of this disease faces
two significant challenges: the increase in incidence of Type 1
diabetes mellitus across the globe [6,7] and the lack of a cure.
Improved understanding of the natural history of this disease
underpins possible solutions to these challenges.
One of the persistent challenges with understanding the natural
history of Type 1 diabetes mellitus is the inability to observe
directly the events in the human pancreas that lead to the onset of
hyperglycemia. It is clear that a reduction in endogenous insulin
production precipitates the onset of hyperglycemia. Knowledge
detailing the pathogenesis in humans is limited to a small number
of biopsy studies from individuals with recent disease onset and to
data from individuals who died soon after diabetes onset [8–11].
Based upon these landmark studies [12], it is a widely held belief
that the onset of hyperglycemia occurs when 80–95% of an
individual’s beta cells are destroyed [13,14]. The level of
destruction may not be so severe as a series of recent studies
suggest that impairment in beta cell function may also contribute
to the emergence of hyperglycemia [15–17].
Quantifying the relative reduction in beta cell mass has
important implications for the design of clinical trials to prevent
or to improve management of the disease [18]. Given that
common wisdom suggests that the reduction in beta cell mass is so
severe at onset, one might conclude that the ability to enhance
beta cell function or preserve the remaining beta cells would have
limited therapeutic potential. In addition, the extent of reduction
at onset can influence the debate [19] over the risk versus benefit
analysis for novel drugs that prolong endogenous insulin
production. Given the clinical importance of this question, the
objective of this study was to re-examine the histopathological
evidence that has long provided the basis for the conceptual
models for the pathophysiology of Type 1 diabetes mellitus. A
meta-analysis was used to extract and assess the significance of
embedded trends within these landmark studies. It was found that
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PLoS ONE | www.plosone.org 1 January 2008 | Issue 1 | e1374the trends observed within these landmark studies do not fully
support the common wisdom that onset of clinical symptoms of
Type 1 diabetes occurs when 80–95% of an individual’s beta cells
are destroyed. An alternative model is proposed where the level of
destruction varies with age and depends on the insulin-producing
capacity, which is proportional to beta cell mass, and insulin
demand, which is proportional to body weight.
RESULTS
The reduction in beta cell mass for recent onset patients with Type
1 diabetes were extracted from three landmark studies identified in
the literature. For the two studies by Foulis and coworkers, the
percentage reduction in beta cell mass was based on the ratio of
the number of insulin deficient islets to the total number of islets
observed following immunohistochemical staining of serial sections
of the pancreata from Type 1 diabetic patients [8,9]. Concurrent
observation of insulin-deficient and insulin-containing islets
provides an internal control to correct for age-dependent and
experimental variability. This calculation assumed that the density
of islets in pancreata from Type 1 diabetic patients is
representative of age-matched normal controls. To justify this
assumption, it is noted that the number of islets and the density of
somatostatin-secreting delta cells, glucagon-secreting alpha cells,
and other cells of the endocrine pancreas are similar between Type
1 diabetic patients and normal controls [9].
In the study by Gepts [10], the total pancreatic volume and
number of beta cells were reported per area of pancreatic tissue for
both non-diabetic controls and Type 1 diabetic patients. The
calculated reduction in beta cell mass was based on the changes in
density of beta cells within pancreata from diabetic patients, as the
total pancreatic volume for recent onset patients was reported to
be similar to non-diabetic controls. The percentage reduction in
beta cell mass was determined based on the ratio of observed
density of beta cell to the expected beta cell density based on a
patient’s age. As shown in Figure 1, non-linear regression (solid
line) was used to estimate the density of beta cells in non-diabetic
controls (filled circles) as a function of age. In non-diabetic
controls, the density of beta cells in the pancreas declines following
birth and reaches a plateau at 25 years of age. The density of beta
cells for patients diagnosed with Type 1 diabetes mellitus prior to
their death (squares) are also shown in Figure 1.
The reduction in beta cell mass is highly variable among a
subset of 63 patients identified to have died within three weeks of
diagnosis for Type 1 diabetes mellitus (recent onset patients) and
shows dependence on age of diagnosis (see Figure 2). The linear
regression results suggest that a greater reduction in beta cell mass is
required for the onset of hyperglycemia in younger patients
compared to older patients. Quantitatively, linear regression of the
recent onset patients resulted in an intercept and slope of 85.5 (95%
C.I.=75.3 to 95.2) percent and 22.15 (95% C.I.=23.02 to 21.30,
p,0.001) percent year
21, respectively. The subset of recent onset
patientsexhibited considerableinter-individualheterogeneitywhere-
by95%ofthepopulationfallswithin645% of the average reduction
in beta cell mass for a given age (dashed lines).
Individually, the sets of data analyzed in this study exhibit
known heterogeneity due to different measurement techniques and
potential patient selection bias. Thus, it is important to assess how
combining these individual sets of data influences the linear
regression results. A computational Bayesian approach, based
upon a Markov chain Monte Carlo (MCMC) algorithm, was used
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Figure 1. The density of beta cells within a cross-section of a pancreas as a function of age. The density of beta cells were reported for non-
diabetic controls (filled circles) and Type 1 diabetics (open squares) reported by Gepts [10]. A non-linear regression was used to estimate the
expected density of beta cells in non-diabetic controls as a function of age (solid line). In diabetics, the percentage reduction in beta cell mass is
estimated by the ratio of the observed beta cell density in diabetics to the expected density provided by the non-linear regression.
doi:10.1371/journal.pone.0001374.g001
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PLoS ONE | www.plosone.org 2 January 2008 | Issue 1 | e1374to estimate how the uncertainty in the linear regression parameters
changed upon combining sets of data [20]. A 2-dimensional (2-D)
marginal posterior density (2-D MPD) was used to estimate the
confidence regions of the linear regression parameters. In Figure 3,
a single contour line indicates the 2-D MPD region within the
parameter space that contains 95% of the total marginal posterior
density (i.e., the 95% confidence region). The MCMC algorithm
was repeatedly applied to the Gepts data only (red curve), the
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Figure 2. The reduction in beta cell mass is highly variable and depends on age of diagnosis. The data points, shown as black symbols,
summarizes the percentage reduction in beta cell mass in 63 subjects that died within three weeks of diagnosis of type 1 diabetes mellitus from three
different studies (squares [10], diamonds [9], and circles [8]). The solid line represents the linear regression to the patients with recent onset type 1
diabetes mellitus. The 95% confidence intervals that enclose the population of recent onset type 1 diabetics patients are shown by the dashed lines.
doi:10.1371/journal.pone.0001374.g002
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Figure 3. A computational Bayesian estimate of the two-dimensional 95% confidence regions for the linear regression parameters. The
confidence regions for the slope and intercept were estimated from the Gepts data (red) [10], Foulis et al. data (blue) [8,9], and combined data (black).
The curves indicate the parameter values that are enclosed within 95% of the posterior probability density function. The confidence regions
associated with the combined data is a non-linear combination of the confidence regions associated with the Gepts data only and the Foulis et al.
data only.
doi:10.1371/journal.pone.0001374.g003
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This repetitive approach was used to assess how the estimates of
the parameter values change when considering a composite data
set derived from individual sets of data.
To quantify the effect of the inclusion criteria for the analysis, a
series of linear regressions were applied to a subset of patients who
died prior to the cutoff. The cutoff was varied between one week
and 312 weeks after diagnosis. These linear regression results for
various cutoff times are shown in Table 1. The linear regression of
the entire population of 105 patients also exhibits the same general
trends, where the extent of reduction in beta cell mass at onset
decreases with age. The slope and intercept for the linear
regression relationship of the entire population were determined
to be 21.10 (95% C.I.=21.86 to 20.35, p=0.001) percent
year
21 and 79.8 (95% C.I.=70.8 to 89.4) percent, respectively.
DISCUSSION
The results from this meta-analysis suggest that clinical presentation
of Type 1 diabetes mellitus is correlated with a greater percentage loss
in beta cell mass in infants compared to adults. An 85% reduction in
beta cell mass in infants can lead to hyperglycemia. In contrast, as
little as a 40% reduction by 20 years of age is sufficient to induce
hyperglycemia. This meta-analysis also demonstrates the significant
heterogeneity in pathophysiology within a population of Type 1
diabetic patients. In older patients, a lower reduction in beta cell mass
gives riseto the same clinical phenotype. This trend was also observed
qualitatively by Foulis et al. [9]. Given this inconsistency with existing
models for the natural history of the disease [2], an alternative theory
may be proposed to explain this behavior.
A Physiology-based Model for Residual Beta Cell
Mass at Onset
Growth of the human body is a dynamic non-linear process where
different parts of the body grow at different rates. Of particular
relevance to Type 1 diabetes mellitus, body weight changes at a
different rate than beta cell mass. One possible explanation for this
observed trend in residual beta cell mass at onset could be
attributed to the dynamic imbalance between the number of beta
cells and the insulin requirements for a growing body. Individu-
ally, beta cell density and total volume of the pancreas both vary as
a function of age. The age-related growth in total beta cell mass, as
shown in Figure 4 (dotted line), can be estimated by the product of
the beta cell density and the total volume of the pancreas [10].
In addition, changes in body weight can influence how insulin
regulates glucose homeostasis. Cellular response to insulin is
proportional to the concentration of insulin. Concentration is a
derived intrinsic variable and defined as the number of proteins
per unit of volume. As the body grows, the volume in which
proteins are distributed increases. Therefore, the number of insulin
molecules must also increase to maintain a constant concentration
(i.e., elicit the same biological effect). Insulin synthesis and release
by beta cells exhibits a non-linear dependence on glucose
Table 1. The linear regression parameters and corresponding
95% confidence intervals reported as a function of change in
the cutoff date.
......................................................................
Cutoff
Weeks Ndata Slope Bootstrap 95% C.I. Intercept Bootstrap 95% C.I.
13 0 22.58 (21.36 to 23.54) 90.09 (74.84 to 100.73)
24 7 22.59 (21.66 to 23.27) 91.91 (79.64 to 99.99)
36 3 22.15 (21.28 to 22.88) 85.46 (73.58 to 94.25)
67 2 21.92 (21.06 to 22.65) 84.00 (72.15 to 93.14)
10 78 22.05 (21.21 to 22.74) 84.03 (72.51 to 92.55)
15 87 21.45 (20.84 to 21.98) 79.11 (67.82 to 88.25)
26 95 21.46 (20.87 to 21.97) 80.34 (69.78 to 89.14)
52 97 21.42 (20.84 to 21.94) 80.63 (69.97 to 89.32)
104 103 21.16 (20.58 to 21.66) 79.88 (69.28 to 88.22)
312 105 21.10 (20.52 to 21.60) 79.81 (69.20 to 88.31)
C.I.=confidence interval
Ndata=number of patients included in subset
doi:10.1371/journal.pone.0001374.t001
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Figure 4. The growth rates for beta cell mass and total body weight exhibit different kinetics. The changes in beta cell mass (dotted line) and
body weight in kg (solid line) are shown a function of age. The beta cell mass is the product of beta cell density [10] and volume of the pancreas [10].
The change in body weight as a function of age is an average value from male and female growth charts [25].
doi:10.1371/journal.pone.0001374.g004
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synthesize insulin does not vary with age, each beta cell is capable
of contributing a fixed number of insulin proteins per unit of time.
Under normal conditions, beta cells may synthesize only a fraction
of their maximum capability. As the number of beta cells
decreases, the remaining beta cells may increase their individual
contributions to maintain a normal concentration of insulin in the
blood. As the beta cell mass progressively declines, individual
contributions rise until a maximum level of protein synthesis is
reached in the remaining beta cells. A subsequent decline in beta
cell mass results in an inability of the body to maintain an
appropriate concentration of insulin in the plasma.
Clinically, metabolic parameters, such as fasting glucose, are
observed to increase dramatically at the onset of hyperglycemia
[23,24]. Admittedly, these studies were performed in high risk
populations and may not generalizable to the entire Type 1
diabetes patient population. By focusing on patients who died
within three weeks of onset, we hypothesize that the onset of
hyperglycemia is a titration of the beta cell mass required to
maintain glucose homeostasis for a given body weight. A
quantitative relationship can be created to predict the ‘‘excess’’
beta cell mass (EBCM(t)) as a function of age. The ‘‘excess’’ beta
cell mass corresponds to the reduction in beta cell mass that is
required before hyperglycemia occurs. This relationship is derived
from a dynamic mole balance between the source of insulin, which
is proportional to beta cell mass (BCMTotal(t)), and sinks for insulin,
which are proportional to body weight (BWt(t)) [25] (see Appendix
S1). Quantitatively, this relationship can be expressed as:
EBCM(t)~
BCMTotal(t){K:BWt(t)
BCMTotal(t)
|100, ð1Þ
where K is a proportionality constant that provides an estimate of
the required beta cell mass per kilogram of body weight. Using the
patient results for the recent onset group, the value for the
parameter K was estimated to be 499 units of BCM kg
21 (95%
C.I.=458 to 605). The resulting relationship for EBCM(t) as a
function of age is shown in Figure 5 (solid line). The trend obtained
by linear regression (dotted line) and the observed reduction in
beta cell mass in pancreata obtained from the subset of recent
onset patients are also shown for comparison.
Qualitatively, the EBCM relationship exhibits a similar depen-
dence with age, as the youngest patients exhibited the greatest
potential reduction in beta cell mass. The trend also declines with
increasing age, resulting inonly a 40%excessinbeta cellmassbythe
age of 20. In other words, the beta cell mass initially grows at a faster
rate relative to the whole body. The overall beta cell mass plateaus
while the overall body weight steadily increases through 20 years of
age. The net result of the different growth dynamics is that the
‘‘excess’’ beta cell mass declines with age. Qualitatively, the observed
reduction in beta cell mass in recent onsets diabetics appears to be
normallydistributedaroundthepredicted‘‘excess’’betacellmass.In
the youngest patients (age ,three years), the predicted ‘‘excess’’ beta
cell mass appears to be lower that the values observed experimen-
tally. In these younger patients, bias may exist due to aggressive
autoimmune attack on the beta cells coupled with an inability to
identify diabetic symptoms in patients at this young age.
Quantitatively, objective criteria have been established for
selecting among competing models that describe the same
phenomenon. In this study, the two competing models are non-
nested and include the model based upon the linear regression
results (LR model) and physiology-based model (PB model).
Bootstrap resampling with replacement (N=10,000) was used to
estimate the confidence level for model discrimination based on
the Akaike Information Criterion (AIC). At each bootstrapped
sample, the best fit values for the model parameters were used to
calculate the LER for the LR and PB models. A histogram
showing the distribution of bootstrapped LER values is shown in
Figure 6. The AIC for the LR and PB models is calculated to be
0.0317 (dotted line). Based on the experimental data, the LER is
estimated to be 0.1245 and suggests that the PB model should be
rejected. As shown in Figure 6, the confidence level (p-value) for
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Figure 5. Comparison of the observed reduction in beta cell mass versus the LR and PB models. Comparison of the estimate of excess beta cell
mass (solid curve) compared against the trend obtained by linear regression (dotted line) for the measured reduction in beta cell mass in 63 patients
that died within three weeks of diagnosis of type 1 diabetes mellitus from three different studies (squares [10], diamonds [9], and circles [8]).
doi:10.1371/journal.pone.0001374.g005
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statistical significance. Therefore, the PB model is indistinguish-
able from the LR model in describing the reduction in beta cell
mass as a function of age. Moreover, the PB model provides a
mechanistic explanation for the observed trends.
The duration of diabetic symptoms is also thought to influence
the residual beta cell mass. Using the predicted ‘‘excess’’ beta cell
mass, each of the 105 patients can be compared against the
remaining beta cell mass in an average recent onset patient,
matched for age. In Figure 7, the difference between the observed
reduction in beta cell mass and predicted ‘‘excess’’ beta cell mass
for each of the 105 patients are plotted against the duration of
disease. In this figure, the patient population is subdivided into
three groups based upon the duration of disease: duration
,3 weeks (red triangles), 3,duration,23 weeks (black squares),
and duration .23 weeks (blue circles). In the recent onset group,
the residual values appear to distribute normally around the
predicted values. In addition, patients with duration greater than
23 weeks exhibited, on average, a greater loss in beta cell mass than
predicted by the ‘‘excess’’ beta cell mass relationship (p,0.001).
While not statistically significant, patients with an intermediate
duration (3,duration,23 weeks) exhibited, on average, a lower
loss in beta cell mass than predicted by the ‘‘excess’’ beta cell mass
relationship (0.1,p,0.05). This observation may be due to patient
selection bias. Alternatively, this behavior could be attributed to a
regrowth in beta cell mass following initiation of treatment.
However, a regrowth of beta cell mass in humans has never been
observed following onset of clinical symptoms.
Potential Limitations and Sources of Bias
A common concern with meta-analyses is the selective bias that
exists in the published literature towards data that authors,
reviewers, and editors find sufficiently novel to publish [26]. Three
additional studies were identified in the literature [11,27,28] but
were excluded from the analysis due to their small sample sizes
0.2 0.1 0 0.1 0.2 0.3 0.4 0.5 0.6
0
500
1000
1500
2000
2500
Log Error Ratio
F
r
e
q
u
e
n
c
y
Reject PB
model
PB model is
equal or
better than
LR model
Figure 6. Frequency of values for LER determined via bootstrap
resampling with replacement of the residuals. The dotted line
corresponds to the AIC threshold for rejecting the PB model. Rejection
of the PB model is not statistically significant as the associated p-value
equals 0.19.
doi:10.1371/journal.pone.0001374.g006
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Figure 7. The variance in PB model residuals depends on duration of diabetic symptoms. The observed reduction in beta cell mass for all patients
minus the predicted excess beta cell mass matched for age plotted as a function of duration of diabetic symptoms. Patients are grouped into three
subsets. The first subset is patients who died within three weeks of diagnosis (red triangles). The second subset is patients who died between three
and 23 weeks following diagnosis (black squares). The third subset is patients who died greater than 23 weeks following diagnosis (blue circles).
Patients who died greater than 23 weeks following diagnosis exhibited a greater reduction in beta cell mass compared to other groups. The p-values
indicate the level of confidence associated with the hypothesis that the mean residual values are different between the two groups.
doi:10.1371/journal.pone.0001374.g007
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have been introduced due to patient selection. The patients
selected for these studies had died primarily of diabetic
ketoacidosis. The reported pancreata may come from more severe
cases and may be an overestimate of the extent of beta cell
reduction, as most newly diagnosed patients with Type 1 diabetes
mellitus are successfully managed clinically [29].
This analysis suggests that the duration of diabetic symptoms
was insufficiently controlled in previous analyses. Qualitatively, the
studies included in this meta-analysis focused on recent onset
patients. Unfortunately, there is not a consistent definition of
recent onset. By applying a linear regression to all of the reported
histopathology results, the residuals were found to be non-normally
distributed and heteroscedastic (i.e., the variance in residuals
depends on the independent variable, age), suggestive of bias in
patient selection. This could have been a contributing factor to the
high value reported by Gepts for the observed reduction in beta cell
mass in all patients diagnosed with Type 1 diabetes mellitus. This
wasone ofthe motivationstorestricttheanalysistopatientsthatdied
within three weeks of diagnosis. The residuals for this subset of
patients were normally distributed and homoscedastic (i.e., the
variance is independent of the independent variable) (data not
shown). A second motivation for restricting the analysis was that the
clinical practice for metabolic control may have been different at the
time of data collection than the current standard of clinical care. By
limiting the patient selection to three weeks following onset, the
sample size was still sufficiently large and the contribution of
differences in clinical practice could be minimized.
One may argue that younger patients exhibit an aggressive
phenotype compared to older patients and that the linear regression
results merely reflect these differences in severity. Prior to onset,
patients who will develop Type 1 diabetes remain largely
asymptomatic with regard to fasting plasma glucose [23,24,30,31].
Post-onset, the presence of C-peptide, produced in equimolar
quantities as insulin, is used as a marker of endogenous insulin
production [32,33]. Following a brief increase post-onset, C-peptide
continues to decline in the years following onset. In Figure 8, a
diagram is used to illustrate the influence of severity on the potential
range of observed reduction in beta cell mass at the time of death. As
the difference between the age at diagnosis and the cutoff for age at
death is large, the observable range in the remaining beta cell mass
gives a lower meanvalue for an aggressivephenotype than for a mild
phenotype. However as the difference between age at diagnosis and
cutoff for age at death (Dage) goes to zero, there is no difference in
the ranges in beta cell mass for aggressive versus mild phenotypes.
This is another motivation for restricting the analysis to patients that
died within three weeks of diagnosis. Moreover, if differences in
severity exhibited age bias (i.e., younger are severe and older are
mild), one would expect that as Dage is reduced the measured slope
should increase (i.e., becomes less negative). This trend is not
observed in Table 1. Alternatively, a fast rate of decline in C-peptide
inyoungerpatientscompared to olderpatientscould beattributedto
volumeofdistribution effectsasyoungerpatientsgrowata fasterrate
than older patients.
In the years since the publication of these landmark studies, a
number of criticisms have been raised regarding the methods used
in these studies to accurately assess beta cell mass. In the Gepts
study [10], a series of non-specific methods were used to identify
beta cells and islets within cross-sections of pancreata, as this study
was performed prior to the advent of histological techniques for
detecting insulin. In comparison to modern immunohistological
techniques, it is unknown how sensitive these non-specific methods
are in detecting difference in changes in beta cell mass. The 2-D
MPD was used to assess this potential source of bias.
As shown in Figure 3, there is greater uncertainty in the
selection of the slope and intercept parameters in the Gepts study,
due in part to the smaller sample size (N=12). This is reflected in
the greater area enclosed by the 95% confidence region of the 2-D
Figure 8. The influence of disease severity on the range of observed reduction in beta cell mass. The diagnosis for Type 1 diabetes occurs once
the beta cell mass declines to a point where the excess beta cell mass (EBCM) is depleted (dotted line). The range of observed reduction in beta cell
mass is greater in patients with severe autoimmunity to beta cells compared to patients with mild autoimmunity when Dage is greater than zero. As
Dage is decreased, the difference in observed reduction in beta bell mass is also decreased.
doi:10.1371/journal.pone.0001374.g008
b Cell Mass at Onset of T1D
PLoS ONE | www.plosone.org 7 January 2008 | Issue 1 | e1374MPD shown in Figure 3 (red line). Conversely, the 95%
confidence region is smaller for the data derived from the Foulis
studies (blue line) as a larger number of observations were reported
(N=51). In general, the slope and intercept were higher using only
the Gepts data compared to the Foulis data only. Interestingly, the
95% confidence 2-D MPD region obtained from the combined
data is not a weighted linear combination of the individual
analysis, as the intercept for the combined data set shifts to lower
value relative to either the Gepts or the Foulis confidence regions.
This effect may be due to a non-normal distribution in sampling
(i.e., bias) inherent in the small size of the Gepts study. In the
analysis of the combined data, the Bayesian approach provided
similar estimates of the confidence intervals as the Bootstrap
approach. As shown in Figure 3, one-dimensional projections of
the 2-D 95% confidence regions obtained by a Bayesian analysis
were similar to the confidence bounds obtained by the non-
parametric Bootstrap approach, shown in Table 1. In both cases,
the 95% confidence regions associated with the slope parameter
are entirely below -1 and provide support for the conclusion that
the reduction in beta cell mass at the onset of clinical symptoms of
Type 1 diabetes mellitus is dependent on the age of onset.
In studies reported by Foulis et al. [8,9], islets were classified as
either insulin-positive or insulin-negative. This binary classification
approach may provide an overestimate of the remaining beta cell
mass, as insulin-positive islets may exhibit a reduced complement of
beta cells compared to age-matched controls. Yet as demonstrated
by several authors [11,28], the pattern of beta cell destruction within
the pancreas is markedly heterogeneous, whereby pancreatic islets
with no beta cell destruction can be located nearby fully destroyed
islets devoid of beta cells. This binary classification scheme only
overestimates the remaining beta cell mass in islets with an
intermediate complement of beta cells. A more quantitative
assessment of the beta cell mass would need to account for both
changes in beta cell numbers within insulin-positive islets and
changesinthedistributionofinsulincontentwithinthepopulationof
islets. In summary, there are potential sources of bias in the original
data that may influence the conclusions derived from the data
analysis. Limited by these data, corrective action, such as restricting
the analysis to data obtained prior to three weeks post onset, was
taken to minimize the contribution of sampling bias.
Conclusions
In summary, the fundamental characteristic of Type 1 diabetes
mellitus is the loss of endogenous insulin production. A series of
landmark studies attributed this loss of endogenous insulin
production to the progressive and selective destruction of beta
cells in the pancreatic islets of Langerhans. In contrast to other
interpretations of these data, this study explicitly accounted for the
duration of diabetic symptoms in determining the extent of
reduction in beta cell mass at disease onset. By re-examining the
data obtained from the pancreata of patients who died soon after
diagnosis, the extent of beta cell death was found to vary with age,
whereby a 40% reduction at 20 years of age is sufficient to
precipitate clinical symptoms of Type 1 diabetes mellitus. Thus,
the statement that an 80–95% reduction in beta cell mass is
necessary for the onset of hyperglycemia appeared to be an
overestimate for most patients. As an alternative to existing models
for the natural history of the disease, the observed age dependence
was explained using a model based upon a dynamic mole balance
on insulin. This dynamic mole balance included a source for
insulin, which is proportional to the beta cell mass, and sinks for
insulin, which are proportional to body weight, and captured the
observed age-dependence. These results emphasize the opportu-
nity to preserve endogenous insulin production, especially in older
patients, if aggressive action is taken once patients present with
Type 1 diabetes mellitus. Moreover, these results suggest a more
holistic model where autoimmune-mediated destruction of
pancreatic beta cells is important but insufficient to reconstruct
the natural history of the disease.
METHODS
Study Selection
The research approach was to apply a meta-analysis to
histopathology studies which reported insulin positive cells in
pancreatic biopsies from patients exhibiting symptoms of Type 1
diabetes mellitus. Three studies were identified where histopathol-
ogies of the endocrine pancreas were quantitatively reported for a
group of young patients. All of the patients were under the age of
25 and had died from primarily diabetic ketoacidosis [8–10]. In
total, 105 patients were included from these three studies.
Calculation of Beta Cell Mass
Histologically, the total beta cell volume can be estimated by
transecting the pancreas and quantifying the area of the transected
surface that contains insulin positive cells (i.e., viable beta cells)
using immunohistochemical techniques. The total volume (i.e.,
mass) of the beta cells (VolBCM) is related to the ratio of insulin-
positive area (AIns+) to total surface area of the transected pancreas
(ATotal), and the total volume of the pancreas (VolPancreas)
according to the following relationship [34]:
VolBCM~
AInsz
ATotal
:VolPancreas ð2Þ
In a summary of post-mortem results for recent onset patients
with Type 1 diabetes mellitus, Gepts [10] and Doniach et al. [35]
reported that pancreatic weight did not differ markedly from the
expected weight, matched for age. Thus, changes in the total beta
cell volume for recent onset patients are assumed to be reflected in
changes in insulin-positive area averaged across cross-sectional
slices of the pancreas.
Statistical Analysis of Reduction in Beta Cell Mass
The histopathology results were stratified into different subsets
based upon the duration of diabetic symptoms. Patients who had
exhibited clinical symptoms of diabetes mellitus for less than three
weeks were grouped into a recent onset subset (Ndata=63). A
linear regression was applied to the recent onset subset to quantify
the dependence between percentage reduction in beta cell mass
and age at death. Using the linear regression results, a residual
value was calculated for each patient to quantify the deviation
from the average behavior. A non-parametric bootstrap approach
was applied to the population of residual values (Ndata=63 or 105)
to estimate confidence intervals and significance of the linear
regression parameters [36]. A bootstrap sample size (Nboot)o f
10,000 was used to estimate the parameter confidence intervals. A
non-parametric bootstrap approach is advantageous as it allows
for the adjustment of confidence intervals when the distribution in
the dependent variables is not known a priori. When the dependent
variables are known to exhibit a Gaussian distribution, the
bootstrap approach provides a good estimate of the confidence
intervals compared against classical statistical techniques, given a
sufficiently large bootstrap sample (i.e., Nboot$1000) and data
sample (i.e., Ndata$30) [37]. The reported significance corre-
sponds to the probability (p) that this relationship does not depend
on age. A p value of less than 0.05 was considered statistically
significant. Repeated analyses were performed by increasing the
b Cell Mass at Onset of T1D
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included in the analysis. Tests of significance between the
measured reduction in beta cell mass and predicted ‘‘excess’’ beta
cell mass was performed using the Behrens-Welch test statistic
evaluated against a t distribution with the degrees of freedom
calculated using the Satterthwaite’s approximation [38].
Statistical Analysis of Data Synthesis
A computational Bayesian approach was used to estimate how the
uncertainty in the linear regression parameters changed upon
combining sets of data [20]. The uncertainty in the linear
regression parameters, as predictors of a given set of data, was
represented by a 2-dimensional marginal posterior probability
density of the likely parameter values. The 2-D marginal posterior
probability densities were calculated using kernel marginalization
of the expectation values of the parameters. A 2-dimensional grid of
1006100 kernels (i.e., histogram bins) were created within a range
of potential parameter values. A large number of Metropolis-
Hasting samples (Nsample=210,000) within a Markov chain Monte
Carlo (MCMC) algorithm were used to estimate the expectation
values. Lower sampling frequencies also exhibited similar results
(data not shown). Prior to testing Monte Carlo samples of
parameter space, 5,000 equilibration steps were used to establish
the Markov chain. Confidence regions within the parameter space
were identified that enclose 95% of the marginal posterior
probability densities.
Model Discrimination
Objective criteria have been established for discriminating
between competing models by quantifying the trade-off between
model parsimony and model fitness in predicting the dependent
variable [39,40]. The log error ratio (LER) is used to quantify the
relative fitness of the competing models in representing the
dependent variables.
LER~log(error ratio)~log
SSE1
SSE2

ð3Þ
where SSEi is the residual summed squared error for model i.
Positive values for LER favor the selection of model 2, while
negative values favor the selection of model 1. Values for LER
around zero suggest that the models are indistinguishable. The
Akaike Information Criterion (AIC) has been established for
discriminating between competing models [39,40]. This criterion
was established to quantify the trade-off between the relative
fitness of competing models (i.e., LER), the number of adjustable
parameters (M) in a model, and the number of observations of the
dependent variable (Nobs). In comparing two competing models,
Akaike proposed that if
LERw
2:(M2{M1)
Nobs
, ð4Þ
model 1 should be rejected [39]. The AIC establishes a threshold
for testing a hypothesis associated with model fitness. For
comparing non-nested models, a Monte Carlo approach has been
proposed to determine the level of significance associated with
model discrimination [41].
SUPPORTING INFORMATION
Appendix S1 Derivation of Physiology-based Model
Found at: doi:10.1371/journal.pone.0001374.s001 (0.13 MB
DOC)
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